Revolution Medicines, Inc.
revmed.comWhat Do They Do?
Develops targeted cancer medicines for patients with cancers driven by RAS gene changes, including drugs designed to block several forms of RAS alone or in combination with other medicines.
10-K for FY2025, filed Feb 25, 2026We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated…View ↗
We believe tailored RAS(ON) Inhibitors will be useful to serve the diverse landscape of RAS-addicted cancers optimally. In some cases…View ↗
We are advancing a deep pipeline of RAS(ON) Inhibitors, including daraxonrasib, our multi-selective inhibitor, zoldonrasib (RMC-9805), our…View ↗
Who Are Their Customers?
U.S. physicians can prescribe oral daraxonrasib to eligible patients.
8-K, filed Aug 26, 2026Once-daily oral RASONQUE tablets are now available in the United States for physicians to prescribe to eligible patients. The wholesale…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$644.4MView ↗
- ▲ +160% (Loss)
- vs −$247.8M in Q2 FY2025
-
Aug 26, 2026
FDA approves daraxonrasib for certain metastatic pancreatic cancer patients
Once-daily oral tablets are available in the United States for physicians to prescribe to eligible patients.
Sources
8-K, filed Aug 26, 2026
On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with…View ↗
Pipeline focus
The older report included companion inhibitors aimed at other pathway targets alongside direct RAS inhibitors; the latest describes its pipeline as direct RAS inhibitors.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 25, 2026Our research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which we refer to as RAS(ON)…View ↗
Our RAS Companion Inhibitor RMC-4630 is designed as a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway.…View ↗
Our RAS Companion Inhibitor RMC-5552 is designed as a selective inhibitor of hyperactivated mTORC1 signaling in tumors. We are evaluating…View ↗
Who Do They Compete With?
Competes with Amgen, Betta Pharmaceuticals, BMS, D3 BIO, Eli Lilly, GenEros Biopharma, GenFleet Therapeutics, Genhouse Bio, HUYA Bioscience, InventisBio, Jacobio Pharmaceuticals, Merck, Sharpe & Dohme, Roche/Genentech, Shanghai Junshi Biosciences, BridgeBio Pharma, Frontier Medicines, Anocca, Arvinas, Astellas Pharma, and AstraZeneca
10-K for FY2025, filed Feb 25, 2026There are several programs in clinical development targeting KRAS G12C, including programs directed at KRAS(OFF) G12C being conducted by…View ↗
Loading...
